Harvard's xenotransplantation technology developer eGenesis has raised a $100m in its series B round.
US-based gene editing technology developer eGenesis yesterday closed a $100m series B round that featured Leaps by Bayer, an investment vehicle for pharmaceuticals and chemicals producer Bayer.
Fresenius Medical Care Ventures, the investment arm of kidney dialysis clinic operator Fresenius Medical Care, led the round, which also included Wellington Partners, Arch Venture Partners, Biomatics Capital, Alta Partners, Khosla Ventures and unnamed, existing investors.
Leaps by Bayer supplied $50m in funding.
Spun out of Harvard University in 2015,…
